Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Global RNA-Targeted Small Molecules Market to Witness 6.1% Growth during 2022 - 2030

This image opens in the lightbox

News provided by

Absolute Markets Insights

08 Mar, 2022, 15:30 GMT

Share this article

Share toX

Share this article

Share toX

PUNE, India, March 8, 2022 /PRNewswire/ -- According to the report published by Absolute Markets Insights, the global RNA-targeted small molecules market is projected to grow at a CAGR of 6.1% during the forecast period (2021 – 2029). Increased development of genome mapping programs, increased innovative developments, and increased applications are driving the global RNA-targeted small molecules market. Moreover, technological advancement has aided analysts in gathering critical information about public health and epidemiology studies, sequencing viruses and bacteria, and assisting causes that may contribute to virulence. The recent stream of RNA-targeted treatment approvals, along with the global awakening to the potential of mRNA vaccines in the midst of the COVID-19 pandemic, has spurred the development of new pipeline assets. RNA-targeting small molecules are organic compounds with traditional drug properties that can bind to RNA secondary or tertiary structures and change translation patterns, localization, and degradation. Expansion Therapeutics, for instance, provides SMiRNA platform, which identifies druggable RNA structures for the delivery of oral medicines and the transformation of patients' lives. This platform focuses on structured RNA targets that have been shown genetically or evolutionary to cause disease. Bayer is also creating and developing RNA-targeting SMOLs, as well as investigating their potential applications. The company is combining its leading capabilities in SMOL identification and development, as well as preclinical and clinical development, to create a comprehensive new RNA-targeting technology platform. With this endeavour, company aims to continue to strive in the development of innovative SMOL treatments for patients suffering from conditions of high medical need.

Get PDF sample report with all related graphs & charts (pre and post covid-19 impact analysis): https://www.absolutemarketsinsights.com/request_sample.php?id=1078

How Absolute Markets Insights is unique in nature?

The research report on RNA-Targeted Small Molecules Market will include extensive information based on the following pointers:

  • Global Market size and forecast values (2015 – 2030), in terms of revenue (US$ Million) by segments/sub-segments; wherein 2015 to 2020 has been considered as historic years, 2021 as the base year, while 2022 to 2030 has been considered as the forecast period.
  • Split of the market revenue (US$ Million) into all the relevant segments & sub-segments across all major regions/countries.
  • Market Determinants and Influencing Factors
  • Macro-Economic and Micro-Economic Indicators
  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Trends on Global RNA-Targeted Small Molecules Market
  • Exclusive Details on the Effect of the Pandemic
  • Porter's Five Forces Analysis
  • Competitor Landscape
    • Product Benchmarking
    • Market Share Analysis, 2021
    • Global Presence and Growth Strategies
  • The final report will include competitive product benchmarking which will encompass comparison of varied services offered by different market participants on the basis of their features and capabilities that will help you to understand their market offerings. Furthermore, for each company, we will provide information regarding company details, company overview, product offerings, key developments, financial analysis, and SWOT analysis and business strategies.
  • The research study specific to a region, including North America, Europe, Asia Pacific, Middle East & Africa and Latin America, is also available.
  • We offer our reports in different languages which include German, Chinese, French, Russian, Spanish, Arabic, Japanese and Korean amongst others.

mRNA Translation Modulators held a significant share in the RNA-targeted small molecules market in 2021

Messenger RNA (mRNA) is a molecule that acts as an intermediary between genes and proteins, encoding instructions that are directly used to make proteins. It is a promising drug target because, rather than directly targeting the proteins, it provides another way to control protein production. Furthermore, major participants in the global RNA-targeted small molecules market, such as Anima Biotech Inc., have developed mRNA modulation and are contributing to market growth. The company is developing a diverse pipeline of small-molecule mRNA drugs, advancing 18 discovery programs across therapeutic areas at an unprecedented rate. The company's pipeline program includes c-Myc translation inhibitor and mutation agnostic mKras translation inhibitor for Oncology, Tau - Alzheimer's disease and Pain - Nav1.7 translation inhibitor for Neuroscience and Collagen-1 for lung fibrosis and through many fibrotic disorders.

Speak to our analyst in case of queries before buying this report: https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=1078

Cancer Therapeutic Indication dominated the RNA-Targeted Small Molecules Market in 2021

RNAs have been identified as drug targets for a wide range of diseases and infections, including cancer, bacterial and viral infections, inherited genetic disorders, cardiovascular and rheumatic diseases. Skyhawk Therapeutics, Inc. develops a portfolio of small molecule RNA-modifying drug candidates with the potential to improve patients' lives by directly addressing disease causes. Skyhawk's drugs have the ability to modify the expression of target genes that were previously thought to be untreatable in a variety of diseases such as cancer, neurodegenerative, autoimmune, inflammatory, and infectious diseases. SkySTAR (Skyhawk Small molecule Therapeutics for Alternative Modulation of RNA) is a company platform that integrates information from computational, kinetic, and structural models of RNA.

The Impact of COVID-19 Pandemic on the Global RNA-Targeted Small Molecules Market

The World Health Organization (WHO) announced in March 2020 of a novel coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). When COVID-19 cases started to rise around the world, experts realized the virus was especially dangerous for people with heart & respiratory disease and related conditions. Many candidates small-molecule therapies are currently being developed that can suppress both SARS-CoV-2 infection and replication, as well as potentially relieve cytokine storms and other related problems. There are more than a dozen already recognized medications or small molecules that may be useful in combating the novel coronavirus' infectious process, such as zinc and chloroquine. These factors are significantly fueling the market growth. Similar initiatives by companies to adapt more seamlessly to changing market conditions demonstrate positive growth prospects for the global RNA-targeted small molecules market during the forecast period.

View our exclusive press releases on Industry Global News24

North America held the Largest Share in the Global RNA-Targeted Small Molecules Market in 2021

According to the global figures, in 2021, North America held the largest market share in the RNA-targeted small molecules market. Countries such as the United States, Canada, and Mexico have made significant investments in the pharmaceutical sector for drug development. Furthermore, the headquarter of major players helps in the growth of the market in this region. Key players are focusing on drug development as well as the incorporation of advanced technologies in order to produce small molecules drugs, which is favouring the region's growth in the global market.

The key market participants operating in the global RNA-targeted small molecules market are:

  • ACCENT THERAPEUTICS
  • Anima Biotech Inc.
  • Arrakis Therapeutics
  • AstraZeneca
  • Bayer AG
  • Epics Therapeutics
  • Expansion Therapeutics
  • F. Hoffmann-La Roche Ltd
  • H3 Biomedicine Inc.
  • Novartis AG
  • PTC Therapeutics
  • Ribometrix
  • SERVIER LABORATORIES
  • Skyhawk Therapeutics, Inc.
  • Other Market Participants

Purchase the latest in-depth RNA-Targeted Small Molecules Market report: https://www.absolutemarketsinsights.com/checkout?id=1078

Global RNA-Targeted Small Molecules Market:

  • By Offering
    • mRNA Translation Modulators
    • RNA Splicing Modification
    • Direct RNA Targeting
    • Others
  • By Therapeutic Indication
    • Lung Fibrosis
    • Cancer
    • Neurodegenerative Diseases
    • Autoimmune
    • Inflammatory
    • Others
  • By End Users
    • Hospitals
    • Research Laboratories
    • Pharmaceutical and Biotechnology Companies
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
      • Rest of North America
    • Europe
      • France
      • The UK
      • Spain
      • Germany
      • Italy
      • Nordic Countries
        • Denmark
        • Finland
        • Iceland
        • Sweden
        • Norway
      • Benelux Union
        • Belgium
        • The Netherlands
        • Luxembourg
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • New Zealand
      • Australia
      • South Korea
      • Southeast Asia
        • Indonesia
        • Thailand
        • Malaysia
        • Singapore
        • Rest of Southeast Asia
      • Rest of Asia Pacific
    • Middle East & Africa
      • Saudi Arabia
      • UAE
      • Egypt
      • Kuwait
      • South Africa
      • Rest of Middle East & Africa
    • Latin America
      • Brazil
      • Argentina
      • Rest of Latin America

Browse more trending reports by Absolute Markets Insights:

  • RNA Based Therapeutics Market – Global RNA based therapeutics market was valued at US$ 4721.82 Mn in 2020 and is anticipated to grow at a CAGR of 16.87% over the forecast period.
  • MRNA Vaccines Market – The global mRNA vaccine market is estimated to witness a compound annual growth rate of 19.76% over the forecast period
  • DNA/RNA Extraction Kit Market – Global DNA/RNA extraction kit market generated a revenue of US$ 586.56 Mn in 2018 and is anticipated to accelerate at a CAGR of 6.8% over the period of next eight years.
  • Real Time PCR (QPCR) Market – Global real time PCR (QPCR) market was valued at US$ 4154.9 Mn in 2018 and is anticipated to reach US$ 8890.5 Mn by 2027, growing at a CAGR of 8.8% over the forecast period.
  • Targeted Antibiotics Market – Global targeted antibiotics market was valued at US$ 19915.11 Mn in 2018 and reach US$ 21031.51 Mn by 2027, growing at a CAGR of 4.4% over the forecast period.
  • Plasma Separation Membrane Market – Global plasma separation membrane Market was estimated to be US$ 405 million in 2020 and is expected to reach US$ 990.19 million by 2029, growing at an estimated CAGR of 20.3% over the forecast period.

Glance through Absolute Markets Insights plethora of reports on Healthcare Category

About Us:

Absolute Markets Insights assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization. From the in-depth analysis and segregation, we serve our clients to fulfill their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.

Contact Us:

Contact Name: Shreyas Tanna
Company: Absolute Markets Insights
Email Id: sales@absolutemarketsinsights.com
Phone: IN +91-7400-24-24-24, US +1-510-420-1213
Website: www.absolutemarketsinsights.com

Logo: https://mma.prnewswire.com/media/1761877/AMI_Logo.jpg 

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.